<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817540</url>
  </required_header>
  <id_info>
    <org_study_id>3-2021-0026</org_study_id>
    <nct_id>NCT04817540</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)</brief_title>
  <official_title>Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we prospectively analyzed molecular subtyping through the PAM 50 test in&#xD;
      HER2-negative (IHC1+ or 2+ (FISH/SISH-)) breast cancer patients. A phase 2 single arm study&#xD;
      was designed to determine whether the addition of HER2-targeted treatment with treatment&#xD;
      increases the pathologic remission rate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response rate (%, ypT0/isN0)</measure>
    <time_frame>12 weeks</time_frame>
    <description>TPathologic Complete Response (pCR) rate, assessed as no evidence of invasive disease in excised surgical specimens of breast and/or axilla(ypT0/isYpN0), in participants who received at least 1 cycle of herzuma and taxane in HER2-enriched subtype breast cancer</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study</condition>
  <arm_group>
    <arm_group_label>Single arm, Herzuma arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herzuma</intervention_name>
    <description>8mg/kg IVF loading dose at first cycle -&gt; 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle</description>
    <arm_group_label>Single arm, Herzuma arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathologically and cytologically documented unsectable/metastatic breast cancer that :&#xD;
&#xD;
             A. has confirmed HER2 negative expression regardless hormone receptor status&#xD;
&#xD;
               -  definition of HER2 negative breast cancer i) HER2 IHC 1+ without ISH or ii) HER2&#xD;
                  IHC 2+ and ISH negative (average HER2 gene copy number &lt;4 signals/cell in single&#xD;
                  probe ISH or HER2/CEP17 ratio &lt;2.0 &amp; average HER2 gene copy number &lt;4 signals&#xD;
                  cell in dual-probe ISH)&#xD;
&#xD;
          2. No prior treatment of stage II-III breast cancer&#xD;
&#xD;
               -  HR+ &amp; HER2- breast cancer : cT1-4N1-3&#xD;
&#xD;
               -  HR- &amp; HER2- breast cancer : cT1N1-3 or cT2-4N0-3&#xD;
&#xD;
          3. No systemic metastasis confirmed by pathological or radiological evaluation&#xD;
&#xD;
          4. Patients over 19 years&#xD;
&#xD;
          5. Confirmed to HER2-enriched subtype by PAM50 study&#xD;
&#xD;
          6. Available FFPE 15-20 slides for evaluating PAM50 study&#xD;
&#xD;
          7. ECOG 0-1&#xD;
&#xD;
          8. Adequate bone marrow functions i) Hemoglobin≥ 9g/dL ii) ANC ≥1,500/mm3 iii) Platelet&#xD;
             ≥100,000/mm3&#xD;
&#xD;
          9. Adequate renal functions i) creatinine : ≤ 1.5 x UNL or ii) creatinine clearance (Ccr)&#xD;
             ≥ 50 ml/min by Cockroft formula&#xD;
&#xD;
         10. Adequate liver functions i) Bilirubine : ≤ 1.5 x UNL ii) AST/ALT : ≤ 2.5 x UNL&#xD;
&#xD;
         11. Adequate cardiac functions&#xD;
&#xD;
               -  LVEF ≥50% (with MUGA scan or TTE)&#xD;
&#xD;
         12. Females of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 72 hours prior to first dose of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) History of previous treatments of ipsilateral or contralateral invasive breast&#xD;
             cancer 2) Confirmation of systemic distant metastasis of breast cancer 3) History of&#xD;
             other malignancy within the last 5 years, except curatively treated basal cell&#xD;
             carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix,&#xD;
             less than 2cm of thyroid cancer (papillary, follicular, medullary).&#xD;
&#xD;
             4) inflammatory breast cancer (cT4d) 5) bilateral breast cancer(except, multifocal or&#xD;
             multicentric breast cancer) 6) occult breast cancer 7) History of positivity for&#xD;
             hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus (HIV)&#xD;
             8) Woman of childbearing potential who is not consenting to use highly effective&#xD;
             methods of birth control (eg, true abstinence [periodic abstinence (eg calendar&#xD;
             ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable&#xD;
             methods of contraception], sterilization, or other non-hormonal forms of&#xD;
             contraception) during treatment 9) Uncontrolled infections and other serious diseases&#xD;
             or medical conditions 10) Uncontrolled hyeprtension or clinically active&#xD;
             cardiovascular disease: for example, cerebrovascular accident or transient isschemic&#xD;
             attack, unstable angina, myocaridal infarction within 6 months prior to enrolment.&#xD;
             Have symptomatic congestive heart failure (CHF; New York Heart Association II-IV) or&#xD;
             symptomatic or poorly controlled cardiac arrhythmia.&#xD;
&#xD;
             11) Have any condition (eg, psychological, geographical, or medical) that does not&#xD;
             permit compliance with the study and follow-up procedures or suggest that the patient&#xD;
             is, in the investigator's opinion, not an appropriate candidate for the study 12)&#xD;
             Patients who are hypesenstivie reaction to experimental drugs (doxorubicin,&#xD;
             cyclophosphamide, paclitaxel, docetaxel, herzuma) 13) Peripheral neuropathy CTCAE&#xD;
             v4.03 ≥ grade 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>April 25, 2021</last_update_submitted>
  <last_update_submitted_qc>April 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Joon Jeong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

